ClinicalTrials.Veeva

Menu

A Study on the Effects of TA-8995 on Lp(a) in Subjects With Elevated Lp(a)

X

Xention

Status and phase

Completed
Phase 2
Phase 1

Conditions

Elevated Lp(a)

Treatments

Drug: TA-8995
Drug: Placebo

Study type

Interventional

Funder types

Industry

Identifiers

NCT02241772
TA-8995-06

Details and patient eligibility

About

A study in males and females with elevated Lp(a) to look at the effects of TA-8995 on Lp(a) levels.

Enrollment

42 patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Male and female (of non-child bearing potential) subjects with elevated Lp(a) levels

Exclusion criteria

  • Clinically significant medical history
  • Abnormal laboratory results (other than lipid levels) or vital signs
  • Receiving any other drug therapy

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

42 participants in 3 patient groups, including a placebo group

10mg TA-8995
Experimental group
Description:
10mg TA-8995 once daily
Treatment:
Drug: TA-8995
2.5mg TA-8995
Experimental group
Description:
2.5mg TA-8995 once daily
Treatment:
Drug: TA-8995
Placebo to TA-8995
Placebo Comparator group
Description:
Placebo to TA-8995 once daily.
Treatment:
Drug: Placebo

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems